# OnCo record aaml0531 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/aaml0531/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "aaml0531", "NCT00372593" ;
  schema:name "COG AAML0531"@en ;
  schema:description "Adding the antibody-drug conjugate gemtuzumab ozogamicin to chemotherapy lowered the chance of relapse in children with acute myeloid leukaemia. Years after the drug had been withdrawn from the US market, this trial helped bring it back for children."@en ;
  schema:url <https://onco.cc/trials/aaml0531/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00372593>, <https://doi.org/10.1200/JCO.2014.55.3628> ;
  onco:status "positive" ;
  onco:tag "nci-coverage", "paediatric", "haematologic" ;
  onco:phase "3" ;
  schema:startDate "2006-08" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-paediatric/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd33/> ;
  onco:drugs <https://onco.cc/drugs/gemtuzumab-ozogamicin/>, <https://onco.cc/drugs/cytarabine-7-3/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:trials <https://onco.cc/trials/alfa-0701/> .